Additionally, preclinical evidence suggests GLP-1 may promote the production of brain-derived neurotrophic factor (BDNF), a protein essential for neuronal growth, differentiation, and long-term memory formation
However, starting in July 2026, a new program called the BALANCE Model may give eligible Medicare Part D beneficiaries access to certain GLP-1 weight loss medications for a $50 copay
Consumption recommendation: 1 capsule daily with food
[1] [3] Marketed under the brand names Mounjaro (for diabetes) and Zepbound (for weight management), tirzepatide represents the first dual incretin receptor agonist available in clinical practice
Our healthcare providers make prescribing decisions based on the medical information you provide during the consultation, including your health history, current medications, and any relevant symptoms or conditions
stage 1 to stage 2A (Siddiqi and Mehra, 2020)